作者
Alwin Krämer,Tilmann Bochtler,Chantal Pauli,K-K. Shiu,Natalie Cook,J. Menezes,Roberto Pazo-Cid,Ferrán Losa,Debbie Robbrecht,Jiří Tomášek,Çağatay Arslan,Mustafa Özgüroğlu,Michael Stahl,Frédéric Bigot,Sun‐Young Kim,Yoichi Naito,Antoîne Italiano,Nasséra Chalabi,Gonzalo Durán-Pacheco,Camille Michaud,Jeremy Scarato,Marlène Thomas,Jeffrey S. Ross,Holger Moch,Linda Mileshkin
摘要
Patients with unfavourable subset cancer of unknown primary (CUP) have a poor prognosis when treated with standard platinum-based chemotherapy. Whether first-line treatment guided by comprehensive genomic profiling (CGP) can improve outcomes is unknown. The CUPISCO trial was designed to inform a molecularly guided treatment strategy to improve outcomes over standard platinum-based chemotherapy in patients with newly diagnosed, unfavourable, non-squamous CUP. The aim of the trial was to compare the efficacy and safety of molecularly guided therapy (MGT) versus standard platinum-based chemotherapy in these patients. This was to determine whether the inclusion of CGP in the initial diagnostic work-up leads to improved outcomes over the current standard of care. We herein report the primary analysis.